Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.

Cancer genomics & proteomics - 1 Jan 2000

Torralvo Javier, Friedlaender Alex, Achard Verane, Addeo Alfredo

Abstract excerpt

BACKGROUND/AIM: KRAS mutation is the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC). It is associated with a poor prognosis without available targeted therapy. Treatment options for NSCLC have been recently enriched by the development of immune checkpoint inhibitors (ICIs), and data about their efficacy in patients with KRAS-mutant NSCLC are discordant. This study assessed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Immunotherapy

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 31659111
DOI: 10.21873/cgp.20160
PMCID: PMC6885372

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.PMID 31659111Read ↗

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.Semantic proximity Read ↗

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read ↗

Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.Semantic proximity Read ↗

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Semantic proximity Read ↗

Treating KRAS -mutant NSCLC: latest evidence and clinical consequencesSemantic proximity Read ↗

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.Semantic proximity Read ↗

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).Semantic proximity Read ↗

Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysisSemantic proximity Read ↗

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.Semantic proximity Read ↗

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study.Semantic proximity Read ↗

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.